These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 24048805)
21. [Endocrine therapy for localized or locally advanced prostate cancer]. Fontaine E; Ruffion A; Staerman F Prog Urol; 2004 Jun; 14(3):433-6. PubMed ID: 15373195 [TBL] [Abstract][Full Text] [Related]
22. The role of endocrine therapy in the management of local and distant recurrence of prostate cancer following radical prostatectomy or radiation therapy. Mayer FJ; Crawford ED Urol Clin North Am; 1994 Nov; 21(4):707-15. PubMed ID: 7974899 [TBL] [Abstract][Full Text] [Related]
23. Androgen deprivation therapy during and after post-prostatectomy radiotherapy in patients with prostate cancer: a case control study. Kim M; Song C; Jeong IG; Choi SK; Park M; Shim M; Kim YS; You D; Hong JH; Kim CS; Ahn H BMC Cancer; 2018 Mar; 18(1):271. PubMed ID: 29523103 [TBL] [Abstract][Full Text] [Related]
24. [Study of sexual hormone changes in prostate cancer patients before and after androgen deprivation therapy]. Ying J; Yao DH; Ren XM Zhonghua Nan Ke Xue; 2003 Jun; 9(3):191-2, 196. PubMed ID: 12861832 [TBL] [Abstract][Full Text] [Related]
32. Use of androgen deprivation and salvage radiation therapy for patients with prostate cancer and biochemical recurrence after prostatectomy. Ghadjar P; Aebersold DM; Albrecht C; Böhmer D; Flentje M; Ganswindt U; Höcht S; Hölscher T; Sedlmayer F; Wenz F; Zips D; Wiegel T; Strahlenther Onkol; 2018 Jul; 194(7):619-626. PubMed ID: 29383406 [TBL] [Abstract][Full Text] [Related]
33. Prostate-specific antigen level at initiation of hormonal therapy after prostate-specific antigen failure following prostatectomy or radiotherapy and therapeutic response. Alexander BM; Chen MH; Carroll P; D'Amico AV Urology; 2007 Aug; 70(2):320-3. PubMed ID: 17826497 [TBL] [Abstract][Full Text] [Related]
34. Prostate cancer (non-metastatic). Wilt T Clin Evid; 2003 Jun; (9):973-85. PubMed ID: 12967402 [No Abstract] [Full Text] [Related]
35. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. Tsai HK; D'Amico AV; Sadetsky N; Chen MH; Carroll PR J Natl Cancer Inst; 2007 Oct; 99(20):1516-24. PubMed ID: 17925537 [TBL] [Abstract][Full Text] [Related]
36. Low rates of androgen deprivation therapy use with salvage radiation therapy in patients with prostate cancer after radical prostatectomy. Yang DD; Muralidhar V; Mahal BA; Nezolosky MD; Labe SA; Vastola ME; Boldbaatar N; King MT; Martin NE; Orio PF; Choueiri TK; Trinh QD; Den RB; Spratt DE; Hoffman KE; Feng FY; Nguyen PL Urol Oncol; 2017 Sep; 35(9):542.e25-542.e32. PubMed ID: 28533151 [TBL] [Abstract][Full Text] [Related]
37. [Treatment of prostate cancer]. Imre R Orv Hetil; 2005 Aug; 146(35):1839-42. PubMed ID: 16187544 [No Abstract] [Full Text] [Related]
38. Does androgen deprivation improve treatment outcomes in patients with low-risk and intermediate-risk prostate cancer? Miyamoto H; Messing EM; Chang C Nat Clin Pract Oncol; 2005 May; 2(5):236-7. PubMed ID: 16264955 [No Abstract] [Full Text] [Related]
39. Prostate cancer. Guthrie TH; Watson P Am Fam Physician; 1987 Oct; 36(4):217-24. PubMed ID: 3314438 [TBL] [Abstract][Full Text] [Related]
40. Controversies in the treatment of prostate cancer with maximal androgen deprivation. McLeod DG; Moul JW Surg Oncol Clin N Am; 1995 Apr; 4(2):345-59. PubMed ID: 7796290 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]